GDF15 and chronic kidney disease: Both lower eGFRdiff and higher GDF‐15 levels were independently associated with adverse outcomes: CKD progression (GDF‐15, hazard ratio [HR] 1.36, 95% CI: 1.02–1.81, p < 0.05; eGFRdiff, HR 0.67, 95% CI: 0.58–0.78, p < 0.0001) and mortality (GDF‐15, HR 2.35, 95% CI: 1.63–3.41, p < 0.0001; eGFRdiff: 0.80, 95% CI: 0.65–0.99, p < 0.05).